Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04150887
Recruitment Status : Recruiting
First Posted : November 5, 2019
Last Update Posted : January 31, 2020
Sponsor:
Collaborator:
argenx BVBA
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

Condition or disease Intervention/treatment Phase
Leukemia, Myeloid, Acute Drug: Cusatuzumab Drug: Azacitidine Drug: Venetoclax Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Actual Study Start Date : December 23, 2019
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : March 30, 2022


Arm Intervention/treatment
Experimental: Cohort 1: Cusatuzumab + Azacitidine (CA)
Participants will receive cusatuzumab 20 milligram per kilogram (mg/kg) intravenously (IV) in combination with azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or IV (as background therapy).
Drug: Cusatuzumab
Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Other Names:
  • JNJ-74494550
  • ARGX-110

Drug: Azacitidine
Azacitidine will be administered 75 mg/m^2 subcutaneously or intravenously.
Other Name: Vidaza

Experimental: Experimental: Cohort 2: Cusatuzumab + Venetoclax (CV)
Participants enrolled in this cohort (applicable only for US sites) will receive cusatuzumab 20 mg/kg IV in combination with venetoclax ramp-up to 400 mg orally (as background therapy).
Drug: Cusatuzumab
Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Other Names:
  • JNJ-74494550
  • ARGX-110

Drug: Venetoclax
Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Other Name: Venclexta

Experimental: Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)
Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
Drug: Cusatuzumab
Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Other Names:
  • JNJ-74494550
  • ARGX-110

Drug: Azacitidine
Azacitidine will be administered 75 mg/m^2 subcutaneously or intravenously.
Other Name: Vidaza

Drug: Venetoclax
Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Other Name: Venclexta




Primary Outcome Measures :
  1. Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of Safety [ Time Frame: Up to 32 months ]
    Frequency and severity of AEs, laboratory abnormalities, and physical exam findings will be reported.


Secondary Outcome Measures :
  1. Serum Concentration of Cusatuzumab [ Time Frame: Up to 32 months ]
    Serum concentration of cusatuzumab will be assessed.

  2. Number of Participants with Anti-cusatuzumab Antibodies [ Time Frame: Up to 32 months ]
    Number of participants with anti-drug antibodies to cusatuzumab will be reported.

  3. Percentage of Participants with Complete Response (CR) [ Time Frame: Up to 32 months ]
    Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported.

  4. Percentage of Participants with Complete Remission with Partial Hematological Recovery (CRh) [ Time Frame: Up to 32 months ]
    Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment.

  5. Percentage of Participants with CR plus CRh [ Time Frame: Up to 32 months ]
    Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment.

  6. Percentage of Participants with CR with Incomplete Recovery (CRi) [ Time Frame: Up to 32 months ]
    Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment.

  7. Overall Response Rate (ORR) [ Time Frame: Up to 32 months ]
    ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment.

  8. Percentage of Participants with CR without MRD [ Time Frame: Up to 32 months ]
    Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than (<) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3).

  9. Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS) [ Time Frame: Up to 32 months ]
    Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as < 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3).

  10. Time to Response [ Time Frame: Up to 32 months ]
    Time to response is defined as time from first dose to achieving the first response of CR, CRh, or CRi.

  11. Duration of Response [ Time Frame: Up to 32 months ]
    Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to hematologic relapse or death of any cause.

  12. Red Blood Cell (RBC) or Platelet Transfusion Independence [ Time Frame: Up to 32 months ]
    Transfusion independence (RBC or platelets) is defined as a period of greater than or equal to (>=) 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of acute myeloid leukemia (AML) according to World Health Organization 2016 criteria . Participants with acute promyelocytic leukemia (APL) with t (15;17) or its molecular equivalent (promyelocytic leukemia/retinoic acid receptor alpha [PML RAR alpha]) are not eligible
  • Must be ineligible for intensive chemotherapy
  • De novo or secondary AML
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Previously untreated AML except: emergency leukapheresis, hydroxyurea, and/or 1 dose 1-2 gram per meter square (g/m^2) cytarabine during the Screening Phase to control hyperleukocytosis. These treatments must be discontinued greater than or equal to (>=) 24 hours prior to start of study drug. Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA must be discontinued >=24 hours prior to the start of study drug
  • Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies

Exclusion Criteria:

  • Leukemic involvement of the central nervous system
  • Eligible for an allogeneic hematopoietic stem cell transplantation at study entry
  • Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug
  • A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screening
  • Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, azacitidine, or their excipients (example: mannitol, an excipient of azacitidine)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04150887


Contacts
Layout table for location contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

Locations
Show Show 37 study locations
Sponsors and Collaborators
Janssen Research & Development, LLC
argenx BVBA
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Additional Information:
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT04150887    
Other Study ID Numbers: CR108710
2019-002808-41 ( EudraCT Number )
74494550AML1003 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: November 5, 2019    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Plan Description:

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Azacitidine
Venetoclax
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors